Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00150735
Status:
COMPLETED
Last Update Posted:
2013-11-26
First Post:
2005-09-06
Brief Title:
Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
A Multicenter Double-blind Randomized Parallel Group Positive-controlled Trial Comparing the Efficacy and Safety of Levetiracetam 1000 to 3000 mgDay Oral bid to Carbamazepine 400 to 1200 mgDay Oral bid Used as Monotherapy for up to a Maximum of 121 Weeks in Subjects 16 Years Newly or Recently Diagnosed as Suffering From Epilepsy and Experiencing Partial or Generalized Tonic-clonic Seizures
Status:
COMPLETED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A double-blind trial comparing the efficacy and safety of levetiracetam to carbamazepine used as monotherapy in subjects 16 years newly or recently diagnosed as suffering from epilepsy and experiencing partial or generalized tonic-clonic seizures
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None